Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Netilmicin (Netromycin, Schering-Plough).

D R Guay

    Drug Intelligence & Clinical Pharmacy
    |February 1, 1983
    PubMed
    Summary

    Netilmicin sulfate, a new aminoglycoside, shows limited therapeutic advantages over existing drugs like gentamicin and amikacin. Its higher cost and similar efficacy restrict its potential value in clinical settings.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin.

    Clinical therapeutics·2002
    Same author

    Adjunctive agents in the management of chronic pain.

    Pharmacotherapy·2001
    Same author

    Pet-assisted therapy in the nursing home setting: potential for zoonosis.

    American journal of infection control·2001
    Same author

    Pharmacokinetics and tolerability of extended-release clarithromycin.

    Clinical therapeutics·2001
    Same author

    An update on the role of nitrofurans in the management of urinary tract infections.

    Drugs·2001
    Same author

    Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.

    The Pediatric infectious disease journal·2001

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Therapeutics

    Background:

    • Netilmicin sulfate is a novel aminoglycoside antibiotic, a derivative of sisomicin.
    • Its therapeutic role compared to gentamicin, tobramycin, and amikacin is under investigation.
    • Preliminary studies suggest potentially lower nephrotoxicity and ototoxicity than other aminoglycosides.

    Purpose of the Study:

    • To establish the therapeutic place of netilmicin sulfate in comparison to existing aminoglycosides.
    • To evaluate netilmicin's efficacy against gentamicin/tobramycin-resistant organisms.
    • To assess netilmicin's toxicity profile and clinical utility.

    Main Methods:

    • Comparative analysis of antimicrobial spectrum and toxicity data.
    • In vitro susceptibility testing against resistant bacterial strains.
    • Review of preliminary animal and human toxicity data.

    Main Results:

    • Netilmicin sulfate demonstrates a similar antimicrobial spectrum to gentamicin, tobramycin, and amikacin, with reduced activity against Pseudomonas aeruginosa.
    • Preliminary animal studies suggest a lower incidence of nephrotoxicity and ototoxicity.
    • Amikacin remains the preferred choice for gentamicin/tobramycin-resistant organisms.

    Conclusions:

    • Netilmicin sulfate has not demonstrated significant advantages over existing aminoglycosides (gentamicin, tobramycin, amikacin).
    • Its higher cost further limits its potential clinical value.
    • Further research is needed to fully define its niche, if any, in aminoglycoside therapy.

    Related Experiment Videos